Summary
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
History
RedHill Biopharma was founded in 2009 and is headquartered in Tel Aviv, Israel. The company is engaged in the development, manufacture and commercialization of biopharmaceuticals and advanced delivery technologies to address unmet medical needs.
Mission
RedHill's goal is to be the leading biopharma provider of innovative and affordable treatments that have the potential to improve patient outcomes and quality of life.
Vision
RedHill is committed to developing breakthrough therapies that make a difference in the lives of patients living with gastrointestinal diseases.
Key Team
Mr. Adi Frish (Chief Corp. & Bus. Devel. Officer)
Mr. Rick D. Scruggs (Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director)
Kristin Comer (VP, Gen. Counsel & Chief Compliance Officer)
Dr. Mark L. Levitt M.D., Ph.D. (Chief Scientific Officer)
Ms. Valerie Graceffa (VP of Sales)
Ms. Alexandra Okmian (Sr. Bus. Devel. & Investor Relations Mang.)
Mr. Rob Jackson (Sr. VP of Sales & Marketing)
Recognition and Awards
Redhill Bio has been recognized as one of the top biotechnology companies in Israel and was named one of the Top 50 Israeli Companies by Deloitte in 2014. It also received the BioTech Laureate award for outstanding contribution for creating significant value in biotechnology by the Israeli Ministry of Health in 2016.
References
Israel 